The global clinical trials activity saw a decrease of 12.2% in Q3 2022, when compared with the rolling average of the last four quarters (Q3 2021 to Q2 2022), according to GlobalData.

Of the overall activity, industry sponsored trials accounted for a 51.8% share in Q3 2022, marking an increase of 1.2% in the total share when compared with the four-quarter average.

Non-industry sponsored trials accounted for a 48.2% share of all the clinical trials globally in Q2 2022, marking a decrease of 1.2% in the overall share when compared with the four-quarter average.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry and non-industry sponsored clinical trials in Q3 2022

Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2022, accounting for a 28.9% share of all trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This was followed by the following therapy areas: Central Nervous System with a 13.9% share, Infectious Disease with a 13.6% share, Metabolic Disorders with an 8.5% share and Gastrointestinal with a 6.7% share.

In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.3% share, followed by Infectious Disease with a 15.7% share, Central Nervous System with a 14.6% share, Metabolic Disorders with an 8.3% share, and Cardiovascular with an 8.2% share.

Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2022
Therapy Area 4-Quarter Avg. Q3 2022 Activity
Oncology 27.3% 28.9% Increase
Central Nervous System 14.6% 13.9% Decrease
Infectious Disease 15.7% 13.6% Decrease
Metabolic Disorders 8.3% 8.5% Increase
Gastrointestinal 7.0% 6.7% Decrease
Cardiovascular 8.2% 6.6% Decrease
Dermatology 5.0% 5.5% Increase
Respiratory 5.9% 4.9% Decrease
Immunology 5.6% 4.4% Decrease
Musculoskeletal Disorders 4.1% 3.8% Decrease
Hematological Disorders 2.9% 3.1% Increase
Ophthalmology 2.9% 3.0% Increase
Women’s Health 1.9% 2.4% Increase
Genito Urinary System And Sex Hormones 2.8% 2.3% Decrease
Genetic Disorders 1.8% 1.9% Increase
Ear Nose Throat Disorders 1.7% 1.2% Decrease
Male Health 1.0% 0.6% Decrease
Mouth and Dental Disorders 0.5% 0.6% Increase
Hormonal Disorders 0.8% 0.5% Decrease
Non Malignant Disorders 0.3% 0.4% Increase
Nutritional Disorders 0.3% 0.2% Decrease

Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q3 2022, accounting for a 26.2% share of all trials.

This was followed by the following therapy areas: Oncology with a 25.8% share, Cardiovascular with a 9.7% share, Infectious Disease with a 9.5% share, and Gastrointestinal with a 6.5% share.

In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 25.5%, followed by Oncology with a 23.4% share, Infectious Disease with a 12.5% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.4% share.

Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2022
Therapy Area 4-Quarter Avg. Q3 2022 Activity
Central Nervous System 25.5% 26.2% Increase
Oncology 23.4% 25.8% Increase
Cardiovascular 8.9% 9.7% Increase
Infectious Disease 12.5% 9.5% Decrease
Gastrointestinal 6.4% 6.5% Increase
Metabolic Disorders 5.4% 6.5% Increase
Musculoskeletal Disorders 5.3% 5.4% Increase
Dermatology 2.6% 3.7% Increase
Respiratory 4.0% 3.7% Decrease
Women’s Health 4.5% 3.6% Decrease
Genito Urinary System And Sex Hormones 2.8% 3.4% Increase
Hematological Disorders 3.0% 2.9% Decrease
Immunology 3.0% 2.9% Decrease
Mouth and Dental Disorders 2.6% 2.9% Increase
Ophthalmology 2.0% 2.2% Increase
Genetic Disorders 0.6% 1.3% Increase
Ear Nose Throat Disorders 1.1% 0.8% Decrease
Nutritional Disorders 0.7% 0.8% Increase
Hormonal Disorders 0.8% 0.7% Decrease
Male Health 0.7% 0.6% Decrease
Non Malignant Disorders 0.3% 0.4% Increase

Top regions in industry and non-industry sponsored clinical trials activity in Q3 2022

Asia-Pacific held the top position for industry sponsored clinical trials activity in Q3 2022 with a 54.3% share, compared to 57.0% in the last four quarters.

North America stood at second place with a 32.3% share in Q3 2022, over 28.5% in the last four quarters, followed by Europe with a 25.6% share in Q3 2022, as against 26.5% in the last four quarters.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 85.6% share in industry sponsored clinical trials in Q3 2022 when compared with 86.0% of average recorded in the last four quarters. Multinational trials accounted for a 14.4% share in Q3 2022, as against the four-quarter average of 14.1%.

Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q3 2022 with a 58.9% share, over 55.3% in the last four quarters.

North America held the second position with a 22.5% share in Q3 2022, over 15.5% in the last four quarters, followed by Europe with a 13.3% share in Q3 2022, as against 13.4% in the last four quarters.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held a 98.8% share for non-industry sponsored clinical trials in Q3 2022, compared to 99.0% in the last four quarters. Multinational trials accounted for a 1.2% share in Q3 2022, as against 1.0% in the last four quarters.

Industry and non-industry sponsored clinical trials by Phase in Q3 2022

Phase I trials outnumbered all other studies with a 36.2% share for industry sponsored trials in Q3 2022, compared to 40.1% average in the last four quarters.

The share of Phase II trials stood at 35.8% in Q3 2022, as against the four-quarter average of 33.5%. Phase III trials held a 17.1% share in Q3 2022, registering an increase of 1.8% over the last four quarters average, followed by Phase IV trials with an 11.0% share in Q3 2022, as against the four-quarter average of 11.1%.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials outnumbered all other trials with a 50.7% share for non-industry sponsored clinical trials in Q3 2022, compared to 44.0% in the last four quarters.

Phase IV trials stood at second place with a 20.6% share in Q3 2022, compared to 22.6% in the last four quarters. Phase I trials held a 17.7% share in Q3 2022, as against 17.1% in the last four quarters, followed by Phase III trials with an 11.1% share in Q3 2022 over 16.4% average recorded in the last four quarters.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.